| Patent application number | Description | Published |
|---|
| 20080260773 | Saccharide Conjugate Vaccines - The invention provides compositions comprising a combination of two or more monovalent conjugates, each of said two or more monovalent conjugates comprising a carrier protein comprising T cell epitopes from two or more pathogens conjugated to saccharide antigen. The invention also provides a multivalent conjugate comprising two or more antigenically distinct saccharide antigens conjugated to the same carrier protein molecule, wherein the carrier protein comprises T cell epitopes from two or more pathogens. Further compositions comprise one or more of said monovalent conjugates and one or more of said multivalent conjugates. The invention further provides methods for making said compositions and uses for said compositions. | 10-23-2008 |
| 20090098157 | Helicobacter Pylori Vaccination - A sterile immunogenic preparation of three purified | 04-16-2009 |
| 20090220544 | ADJUVANTED VACCINES WITH NON-VIRION ANTIGENS PREPARED FROM INFLUENZA VIRUSES GROWN IN CELL CULTURE - An immunogenic composition comprising (i) a non-virion influenza virus antigen prepared from a virus grown in cell culture; and (ii) an adjuvant. Preferred adjuvants comprise oil-in-water emulsions. | 09-03-2009 |
| 20090220545 | Adjuvant-Sparing Multi-Dose Influenza Vaccination Regimen - An influenza vaccine is administered by a multi-dose regimen, in which (i) a first dose is administered with an adjuvant and (ii) a later dose is administered either without an adjuvant or with a different adjuvant. Thus the invention provides the benefits of a two-dose regimen without also doubling the supply need for a given adjuvant. | 09-03-2009 |
| 20100158943 | ADMINISTRATION ROUTES FOR PRIMING/BOOSTING WITH INFLUENZA VACCINES - Patients receive a mucosal influenza vaccine and then receive a parenteral influenza vaccine, in that order, typically during different visits to a vaccination center. | 06-24-2010 |
| 20110150923 | MUCOSAL MENINGOCOCCAL VACCINES - The invention provides immunogenic compositions for mucosal delivery comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of | 06-23-2011 |
| 20110150931 | RAPID RESPONSES TO DELAYED BOOSTER IMMUNISATIONS - Booster immunization can lead to rapid induction of protective immunity against pathogens (e.g. ≦7 days after the booster dose). This rapid response means that booster immunization can be used at short notice prior to an event that might require an activated immune response. For instance, a subject can be primed at a young age against a pathogen that typically affects more elderly subjects under specific circumstances such that, when the subject is older, the immune response can be mobilized rapidly if those specific circumstances are expected. An example would be to prime a subject against infections that are typically acquired nosocomially and then, soon before a scheduled hospital appointment, to boost their immune response so that they enter hospital in an immune-alert state. | 06-23-2011 |
